Stopped: PI left organization and discontinued study
This study will be performed to evaluate the Clinical Outcomes and Quality of Life after Transarterial Radioembolization with Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults with Liver Tumors. The treatment and techniques used here are well established in adults. The purpose of this study is to evaluate: 1. the response to treatment and clinical outcomes of treatment with TARE Y-90 as part of standard therapy and 2. to assess the change in the patient's quality of life before, during and after treatment with TARE-Y90
Age range
0 Years – 21 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)
Timeframe: Assessed at baseline/time of treatment
Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)
Timeframe: Assessed at 1 month post therapy
Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)
Timeframe: Assessed at 6 months post therapy
Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)
Timeframe: Assessed at 12 months post therapy
Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)
Timeframe: Assessed at 5 years post therapy
Evaluate the efficacy and clinical utility of TARE-Y90 by examining 2 year survival
Timeframe: Patients will be assessed at 2 years post therapy
Evaluate the efficacy and clinical utility of TARE-Y90 by examining 5 year survival
Timeframe: Patients will be assessed at 5 years post therapy
Evaluate the efficacy and clinical utility of TARE-Y90 by examining local tumor response
Timeframe: Patients will be assessed at the end of treatment which is typically 2-4 months following treatment
Evaluate the efficacy and clinical utility of TARE-Y90 by examining resection rate
Timeframe: Patients will be assessed at the end of treatment which is typically 2-4 months following treatment.
Evaluate the efficacy and clinical utility of TARE-Y90 by examining Transplant rate
Timeframe: Patients will be assessed at the end of treatment which is typically 2-4 months following treatment.
Evaluate the efficacy and clinical utility of TARE-Y90 by examining histologic response
Timeframe: Patients will be assessed at the end of treatment which is typically 2-4 months following treatment.
Evaluate the efficacy and clinical utility of TARE-Y90 by examining biologic response
Timeframe: Patients will be assessed at the end of treatment which is typically 2-4 months following treatment.
Evaluate the efficacy and clinical utility of TARE-Y90 by examining clinical course
Timeframe: Patients will be assessed at the end of treatment which is typically 2-4 months following treatment.